Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial

Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial

ObjectiveThis study tested the hypothesis that a neuroprotective combined therapy based on epidermal growth factor (EGF) and growth hormone-releasing hexapeptide (GHRP6) could be safe for acute ischemic stroke patients, admitting up to 30% of serious adverse events (SAE) with proven causality.Method...

Full description

Bibliographic Details
Main Authors: Francisco Hernández-Bernal, Donner Estenoz-García, Juan H. Gutiérrez-Ronquillo, Yenima Martín-Bauta, Karen Catasús-Álvarez, Mario Gutiérrez-Castillo, Marbelys Guevara-Rodríguez, Aliuska Castro-Jeréz, Yoandra Fuentes-González, Yulemis Pinto-Cruz, Carmen Valenzuela-Silva, Verena L. Muzio-González, Héctor Pérez-Saad, Nelvys Subirós-Martínez, Gerardo E. Guillén-Nieto, Diana Garcia-del-Barco-Herrera
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Neurology
Subjects:
ischemic stroke
brain ischemia
epidermal growth factor
growth hormone-releasing hexapeptide
clinical trial
combination drug therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1303402/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2024.1303402/full

Similar Items